Department of Psychiatry, Cedars-Sinai Medical Center and David Geffen School of Medicine at UCLA, 8730 Alden Drive, Thalians W-157, Los Angeles, CA 90048, USA.
Curr Psychiatry Rep. 2009 Dec;11(6):503-8. doi: 10.1007/s11920-009-0076-z.
Quality of life (QOL) is greatly diminished in patients with major depressive disorder (MDD) before treatment. This deficit persists even when patients are in remission; thus, interventions are needed to improve QOL. This article reviews QOL impairment in MDD and the cost of impairment, then summarizes the empiric literature on the effects of dopaminergic agents on QOL in patients with MDD. Studies were identified through a MEDLINE search from the past 35 years (1974-2009) using key terms "quality of life," "major depression," and "major depressive disorder," and "dopaminergic," "bupropion," or "modafinil." A total of 47 studies were included in this review. A brief overview of the relationship between QOL and MDD is presented, followed by a review of dopaminergic agent chemistry, mechanism of action, use, and trials conducted to investigate agents' effects on QOL. Preliminary evidence suggests dopaminergic agents may have a positive effect on QOL for patients with MDD. Prospective, randomized, double-blind, placebo-controlled studies are needed to extend these findings.
生活质量（QOL）在接受治疗前患有重度抑郁症（MDD）的患者中大大降低。即使患者缓解后，这种缺陷仍然存在；因此，需要干预措施来改善 QOL。本文综述了 MDD 患者的 QOL 损害及其损害的成本，然后总结了关于 MDD 患者使用多巴胺能药物对 QOL 的影响的经验文献。通过使用关键词“生活质量”、“重度抑郁症”和“重度抑郁障碍”以及“多巴胺能”、“安非他酮”或“莫达非尼”，对过去 35 年（1974-2009 年）的 MEDLINE 进行搜索，确定了研究。共纳入 47 项研究。本文简要介绍了 QOL 与 MDD 之间的关系，然后回顾了多巴胺能药物的化学、作用机制、用途以及进行的关于这些药物对 QOL 影响的试验。初步证据表明，多巴胺能药物可能对 MDD 患者的 QOL 产生积极影响。需要进行前瞻性、随机、双盲、安慰剂对照研究来扩展这些发现。
